FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FRISCO, Texas, Jan. 26, 2016 -- Greatbatch Inc., (NYSE:GB) today announced that a jury in the United States District Court for the District of Delaware returned a verdict finding that AVX Corporation and AVX Filters Corporation infringed two Greatbatch patents, and in the process awarded Greatbatch $37.5 million in damages. The complaint, filed in April 2013, alleged that AVX had infringed Greatbatch patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate its patented technology.
The jury's decision marked an important milestone in Greatbatch’s effort to defend its patented technology. “Greatbatch is committed to challenging willful and deliberate patent infringement and to taking all steps necessary to ensure that our intellectual property is protected,” said Thomas J. Hook, Greatbatch president & CEO. "I want to express my sincere appreciation for the time and careful attention the Court and the jury gave this important case."
During trial, Greatbatch presented evidence that certain AVX products infringed claims of U.S. Patent Nos. 5,905,627 and 5,333,095. In advance of trial, the Court determined that the jury should also include damages for infringement of U.S. Patent No. 6,888,715.
In awarding Greatbatch $37.5 million in damages, the jury also confirmed the validity of Greatbatch’s asserted patents, as well as two other Greatbatch patents that AVX had challenged.
Additional information about the case – Greatbatch Ltd. v. AVX Corporation and AVX Filters Corporation, Civil Action No. 13-cv-723-LPS – can be obtained from publicly available court records. Greatbatch was represented in this case by Harris Beach PLLC.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopaedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company’s brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.greatbatch.com.
In October 2015, Greatbatch, Inc. completed its acquisition of Lake Region Medical, with the combined company expected to be renamed Integer Holdings Corporation later this year (subject to shareholder approval).
Investor Relations Contact: Anthony Borowicz [email protected] tel 716-759-5809 Media Contact: Christopher Knospe [email protected] tel 716-759-5727
